Análisis de la coexpresión de HER2/GRB7 y su asociación con variables clinicopatológicas en un grupo de mujeres colombianas con diagnóstico de cáncer de mama invasivo
DOI:
https://doi.org/10.35509/01239015.885Palabras clave:
neoplasias de la mama, receptor ErbB-2, proteína adaptadora GRB7Resumen
Objetivo. Analizar las diferencias en la presentación de variables clínico-patológicas, de acuerdo con la expresión proteica de GRB7, en tumores HER2 positivos en mujeres colombianas con cáncer de mama invasivo, diagnosticado entre los años 2013 y 2015 en el Instituto Nacional de Cancerología E.S.E (INC).
Métodos. Se incluyeron 158 pacientes con diagnóstico confirmado de cáncer de mama ductal invasivo. Se evaluó la expresión de los receptores hormonales (receptor de estrógeno (RE) y de progesterona (RP)), HER2, Ki67 y GRB7, mediante inmunohistoquímica (IHQ), y a partir de estos, se clasificaron los tumores en subtipos intrínsecos. Los análisis estadísticos incluyeron las pruebas de Chi-cuadrado/test exacto de Fisher para las variables categóricas, y la prueba U Mann Whitney/ Kruskal Wallis para las variables cuantitativas. Se evaluó la supervivencia global (SG) y libre de enfermedad (SLR) según la coexpresión de HER2/GRB7 usando el método de Kaplan-Meier y el test de log-rank.
Resultados. La expresión de GRB7 se observó exclusivamente en tumores HER2-positivos (luminal B/HER2+ y HER2-enriquecidos: p<0,001). Los casos HER2+/GRB7+ mostraron una mayor expresión de Ki67 (40% vs. 27,5%, p=0,029), pero una tendencia a presentar un menor tamaño tumoral (30 mm vs. 51 mm, p=0,097), comparado con los tumores HER2+/GRB7-. No obstante, no se observaron diferencias en la supervivencia según la coexpresión de HER2/GRB7 (SG: p=0,6; SLR: p=0,07).
Conclusiones. En nuestra muestra de estudio, la expresión de GRB7 en tumores HER2+ no se asoció con características clínico-patológicas de pronóstico desfavorable.
Referencias bibliográficas
Ban KA, Godellas CV. Epidemiology of breast cancer. Surg Oncol Clin N Am. 2014;23(3):409–22. http://dx.doi.org/10.1016/j.soc.2014.03.011
Di Sibio A, Abriata G, Forman D, Sierra MS. Female breast cancer in Central and South America. Cancer Epidemiol. 2016;44:S110–20. http://dx.doi.org/10.1016/j.canep.2016.08.010
Lei S, Zheng R, Zhang S, Chen R, Wang S, Sun K, et al. Breast cancer incidence and mortality in women in China: temporal trends and projections to 2030. Cancer Biol Med. 2021;18(3):900–9. https://doi.org/10.20892/j.issn.2095-3941.2020.0523
Barbieri RL. Chapter 10 - Breast. Strauss JF, Barbieri RL, Yen and Jaffe’s Reproductive Endocrinology (Eighth Edition). Elsevier. 2019;248-255.e3. https://doi.org/10.1016/B978-0-323-47912-7.00010-X
Pardo C, de Vries E, Buitrago L, Gamboa Ó. Atlas de mortalidad por cáncer en Colombia. Cuarta edición. Bogotá D. C. Instituto Nacional de Cancerología, 2017, v.1. p. 124.Disponible en: https://www.cancer.gov.co/recursos_user/files/libros/archivos/ATLAS_de_Mortalidad_por_cancer_en_Colombia.pdf
Turashvili G, Brogi E. Tumor heterogeneity in breast cancer. Front Med. 2017;4:1-11. https://doi.org/10.3389/fmed.2017.00227
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52. https://doi.org/10.1038/35021093
Howlader N, Cronin KA, Kurian AW, Andridge R. Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomarkers Prev. 2018;27(6):619–26. https://doi.org/10.1158/1055-9965.EPI-17-0627
Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS. 2001;98(19): 10869 –74. https://doi.org/10.1073/pnas.191367098
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 2011;22(8):1736–47. https://doi.org/10.1093/annonc/mdr304
DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin. 2016;66(1):31–42. https://doi.org/10.3322/caac.21320
Troester MA, Sun X, Allott EH, Geradts J, Cohen SM, Tse CK, et al. Racial differences in PAM50 subtypes in the Carolina Breast Cancer Study. J Natl Cancer Inst. 2018;110(2):1–7. https://doi.org/10.1093/jnci/djx135
Hines LM, Risendal B, Byers T, Mengshol S, Lowery J, Singh M. Ethnic disparities in breast tumor phenotypic subtypes in hispanic and non-hispanic white women. J Women’s Heal. 2011;20(10):1543–50. https://doi.org/10.1089/jwh.2010.2558
Gómez R, Ossa CA, Montoya ME, Echeverri C, Ángel G, Ascuntar J, et al. Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in Hispanic breast cancer patients following neoadjuvant chemotherapy. Ecancermedicalscience. 2015;9:562. https://doi.org/10.3332/ecancer.2015.562
Serrano-Gomez SJ, Sanabria-Salas MC, Hernández-Suarez G, García O, Silva C, Romero A, et al. High prevalence of luminal B breast cancer intrinsic subtype in Colombian women. Carcinogenesis. 2016;37(7):669–76. https://doi.org/10.1093/carcin/bgw043
Pinto JA, Saravia CH, Flores C, Araujo JM, Martínez D, Schwarz LJ, et al. Precision medicine for locally advanced breast cancer: Frontiers and challenges in Latin America. Ecancermedicalscience. 2019;13:896. https://doi.org/10.3332/ecancer.2019.896
Pérez-Rodríguez G, Aranda-Moreno C, Olivares-Corichi IM, Garcia-Sanchez JR. The association of subtypes of breast cancer with tumour characteristics and reproductive factors in 1326 Mexican women. Contemp Oncol (Pozn). 2015;19(6):462–6. https://doi.org/10.5114/wo.2015.56652
Serrano-Gómez SJ, Sanabria-Salas MC, Garay J, Baddoo MC, Hernández-Suarez G, Mejía JC, et al. Ancestry as a potential modifier of gene expression in breast tumors from Colombian women. PLoS One. 2017;12(8):e0183179. https://doi.org/10.1371/journal.pone.0183179
Nencioni A, Cea M, Garuti A, Passalacqua M, Raffaghello L, Soncini D, et al. Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression. PLoS One. 2010;5(2):1–10. https://doi.org/10.1371/journal.pone.0009024
Pradip D, Bouzyk M, Dey N, Leyland-Jones B. Dissecting GRB7-mediated signals for proliferation and migration in HER2 overexpressing breast tumor cells: GTP-ase rules. Am J Cancer Res. 2013;3(2):173–95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23593540%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC3623837
Bivin WW, Yergiyev O, Bunker ML, Silverman JF, Krishnamurti U. GRB7 expression and correlation with HER2 amplification in invasive breast carcinoma. Appl Immunohistochem Mol Morphol. 2017;25(8):553–8. https://doi.org/10.1097/PAI.0000000000000349
Nadler Y, González AM, Camp RL, Rimm DL, Kluger HM, Kluger Y. Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer. Ann Oncol. 2009;21(3):466–73. https://doi.org/10.1093/annonc/mdp346
McCann KE, Slamon DJ. Chapter 1 - The molecular biology of HER2 and HER2-Targeted therapies. In: Hurvitz S, McCann K. HER2-Positive breast cancer. Elsevier. 2019. p. 1–11. http://dx.doi.org/10.1016/B978-0-323-58122-6.00001-5
Luoh SW, Wagoner W, Wang X, Hu Z, Lai X, Chin K, et al. GRB7 dependent proliferation of basal-like, HER-2 positive human breast cancer cell lines is mediated in part by HER-1 signaling. Mol Carcinog. 2019;58(5):699–707. https://doi.org/10.1002/mc.22963
Wolff AC, Elizabeth Hale Hammond M, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/ College of American Pathologists Clinical Practice Guideline focused update. J Clin Oncol. 2018;36(20):2105–22. https://doi.org/10.1200/JCO.2018.77.8738
Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206–23. https://doi.org/10.1093/annonc/mdt303
Vallejos CS, Gómez HL, Cruz WR, Pinto JA, Dyer RR, Velarde R, et al. Breast cancer classification according to immunohistochemistry markers: Subtypes and association with clinicopathologic variables in a Peruvian hospital database. Clin Breast Cancer. 2010;10(4):294–300. http://dx.doi.org/10.3816/CBC.2010.n.038
Ramsey B, Bai T, Hanlon Newell A, Troxell M, Park B, Olson S, et al. GRB7 protein over-expression and clinical outcome in breast cancer. Breast Cancer Res Treat. 2011;127(3):659–69. https://doi.org/10.1007/s10549-010-1010-0
Simon SD, Bines J, Werutsky G, Nunes JS, Pacheco FC, Segalla JG, et al. Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: The AMAZONA retrospective cohort study. Breast. 2019;44:113–9. https://doi.org/10.1016/j.breast.2019.01.008
Kim J, Lee Y, Yoo T, Kim J, Hyun J, Park I, et al. Organ-specific recurrence or metastatic pattern of breast cancer according to biological subtypes and clinical characteristics. J Breast Dis. 2019;7(1):30–7. https://doi.org/10.14449/jbd.2019.7.1.30
Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24(Suppl 2):S26–35. https://doi.org/10.1016/j.breast.2015.07.008
Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: A collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010;7(5):e1000279. https://doi.org/10.1371/journal.pmed.1000279
Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736–50. https://doi.org/10.1093/jnci/djp082
Choi N, Lee SW, Lim Y, Kang E, Kim EK, Kim YJ, et al. Failure patterns between HER2-Negative and HER2-Positive luminal B breast cancer. Ann Breast Cancer. 2019;2(1):1–6. Available from: https://meddocsonline.org/annals-of-breast-cancer/failure-patterns-between-her2-negative-and-her2-positive-luminal-B-breast-cancer.pdf
Ding NH, Liu CF, Hu C, Yuan JQ, Liao WH, Xiao Z. Prognostic factors for luminal B-like breast cancer. Curr Med Sci. 2019;39(3):396–402. https://doi.org/10.1007/s11596-019-2049-8
Hashmi AA, Aijaz S, Khan SM, Mahboob R, Irfan M, Zafar NI, et al. Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients. World J Surg Oncol. 2018;16(1):1–6. https://doi.org/10.1186/s12957-017-1299-9
Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast. 2012;21(1):50–7. http://dx.doi.org/10.1016/j.breast.2011.07.008
Li J, Chen Z, Su K, Zeng J. Clinicopathological classification and traditional prognostic indicators of breast cancer. Int J Clin Exp Pathol. 2015;8(7):8500–5. PMID: 26339424
Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol . 2009;27(34):5700–6. https://doi.org/10.1200/JCO.2009.23.2025
Giricz O, Calvo V, Pero SC, Krag DN, Sparano JA, Kenny PA. GRB7 is required for triple-negative breast cancer cell invasion and survival. Breast Cancer Res Treat. 2012;133(2):607–15. https://doi.org/10.1007/s10549-011-1822-6
Lim RCC, Price JT, Wilce JA. Context-dependent role of Grb7 in HER2+ve and triple-negative breast cancer cell lines. Breast Cancer Res Treat. 2014;143(3):593–603. https://doi.org/10.1007/s10549-014-2838-5
Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, et al. Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer. Clin Cancer Res. 2011;17(22):7194–203. https://doi.org/10.1158/1078-0432.CCR-10-3357
Bai T, Luoh SW. GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation. Carcinogenesis. 2008;29(3):473–9. https://doi.org/10.1093/carcin/bgm221
Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LAG, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5): dju055. https://doi.org/10.1093/jnci/dju055
Zhao HB, Zhang XF, Jia XL, Wang H Bin. Grb7 is over-expressed in cervical cancer and facilitate invasion and inhibit apoptosis in cervical cancer cells. Pathol Res Pract. 2017;213(9):1180–4. http://dx.doi.org/10.1016/j.prp.2017.05.013
Petit T, Wilt M, Velten M, Millon R, Rodier JF, Borel C, et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer. 2004;40(2):205–11. https://doi.org/10.1016/S0959-8049(03)00675-0
Tao M, Chen S, Zhang X, Zhou Q. Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: A meta-analysis. Medicine (Baltimore). 2017;96(51):e9384. https://doi.org/10.1097/MD.0000000000009384
Li X, Krishnamurti U, Bhattarai S, Klimov S, Reid MD, O’Regan R, et al. Biomarkers Predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer. Am J Clin Pathol. 2016;145(6):871–8. https://doi.org/10.1093/ajcp/aqw045
Mendes D, Alves C, Afonso N, Cardoso F, Passos-Coelho JL, Costa L, et al. The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review. Breast Cancer Res. 2015;17(140):1–14. http://dx.doi.org/10.1186/s13058-015-0648-2
Rinnerthaler G, Gampenrieder SP, Greil R. HER2 directed antibody-drug-conjugates beyond T-DM1 in breast cancer. Int. J. Mol. Sci. 2019;20,1115:1–17. https://doi.org/10.3390/ijms20051115
Zlobec I, Terracciano L, Jass JR, Lugli A. Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer. Virchows Arch. 2007;451:763–9. https://doi.org/10.1007/s00428-007-0466-8
Cómo citar
Descargas
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2023 Revista Colombiana de Cancerología
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Todos los derechos reservados.
Datos de los fondos
-
Instituto Nacional de Cancerología
Números de la subvención C19010300-411
